Precision Assays (Commercial Rights To Immuno-MRM Assays) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Precision Assays (Commercial Rights To Immuno-MRM Assays) General Information

Description

The commercial rights of next-generation immuno-MRM assays, which deploys high-end multiplex quantitative immuno-MRM mass spectrophotometry-based assays for its pharmaceutical and biotech industry clients.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • Seattle, WA
  • United States
Primary Industry
Buildings and Property
Acquirer
Corporate Office
  • Seattle, WA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Precision Assays (Commercial Rights To Immuno-MRM Assays) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Precision Assays (Commercial Rights To Immuno-MRM Assays)‘s full profile, request access.

Request a free trial

Precision Assays (Commercial Rights To Immuno-MRM Assays) FAQs

  • Where is Precision Assays (Commercial Rights To Immuno-MRM Assays) headquartered?

    Precision Assays (Commercial Rights To Immuno-MRM Assays) is headquartered in Seattle, WA.

  • What industry is Precision Assays (Commercial Rights To Immuno-MRM Assays) in?

    Precision Assays (Commercial Rights To Immuno-MRM Assays)’s primary industry is Buildings and Property.

  • Is Precision Assays (Commercial Rights To Immuno-MRM Assays) a private or public company?

    Precision Assays (Commercial Rights To Immuno-MRM Assays) is a Private company.

  • What is Precision Assays (Commercial Rights To Immuno-MRM Assays)’s current revenue?

    The current revenue for Precision Assays (Commercial Rights To Immuno-MRM Assays) is .

  • When was Precision Assays (Commercial Rights To Immuno-MRM Assays) acquired?

    Precision Assays (Commercial Rights To Immuno-MRM Assays) was acquired on 17-May-2022.

  • Who acquired Precision Assays (Commercial Rights To Immuno-MRM Assays)?

    Precision Assays (Commercial Rights To Immuno-MRM Assays) was acquired by CellCarta.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process